Shanghai Haoyuan Pharmaceutical Co., Ltd. Convertible Bond Conversion Results and Share Change Announcement

Stock Code: 688131 Stock Short Name: BrightGene Bio-Medical Announcement No.: 2026-007

Bond Code: 118051 Bond Short Name: BrightGene Convertible Bond

Shanghai BrightGene Bio-Medical Co., Ltd.

Announcement on the Results of the Conversion of the Convertible Bond into Shares and Changes in Share Capital

The board of directors of the Company and all members of the board of directors hereby confirm that this announcement contains no false records, misleading statements, or material omissions, and they assume legal responsibility for the authenticity, accuracy, and completeness of the contents of this announcement in accordance with the law.

Key Information Summary:

● Cumulative conversion status: Since Shanghai BrightGene Bio-Medical Co., Ltd. (hereinafter referred to as the “Company”) issued the convertible corporate bond “BrightGene Convertible Bond” to non-specific targets on June 4, 2025, the bond has been eligible for conversion. As of March 31, 2026, a total of RMB 503,000 of “BrightGene Convertible Bond” has been converted into the Company’s shares, with a cumulative number of shares converted of 12,372, accounting for 0.0059% of the total number of shares issued by the Company prior to the conversion of “BrightGene Convertible Bond.”

● Unconverted convertible bond status: As of March 31, 2026, the amount of “BrightGene Convertible Bond” that has not yet been converted is RMB 821,847,000, accounting for 99.94% of the total issuance amount of “BrightGene Convertible Bond.”

● Conversion status this quarter: From January 1, 2026 to March 31, 2026, a total of RMB 12,000 of “BrightGene Convertible Bond” was converted into the Company’s shares, with a conversion quantity of 295 shares, accounting for 0.0001% of the total number of shares issued by the Company prior to the conversion of “BrightGene Convertible Bond.”

I. Overview of the Issuance and Listing of the Convertible Bond

Approved by the China Securities Regulatory Commission’s Reply on Approving the Registration of Shanghai BrightGene Bio-Medical Co., Ltd.’s Registration for the Issuance of Convertible Corporate Bonds to Non-Specific Investors (Zheng Jian Xu Ke [2024] No. 1289), Shanghai BrightGene Bio-Medical Co., Ltd. (hereinafter referred to as the “Company,” and “our Company”) issued 8.2235 million lots of convertible corporate bonds to non-specific investors on November 28, 2024. Each lot has a par value of RMB 100, with a total issuance amount of RMB 822.35 million, and a term of 6 years.

With the approval of the Shanghai Stock Exchange’s self-regulatory decision letter [2024] No. 168, the Company’s convertible corporate bonds were listed and began trading on the Shanghai Stock Exchange starting from December 19, 2024. The bond name is “BrightGene Convertible Bond,” and the bond code is “118051.”

Pursuant to relevant regulations and the provisions of the Company’s “Offering Prospectus for Convertible Corporate Bonds Issued to Non-Specific Investors” (hereinafter referred to as the “Offering Prospectus”), the “BrightGene Convertible Bond” issued by the Company is convertible into the Company’s shares starting from June 4, 2025. The conversion period runs from June 4, 2025 to November 27, 2030. The initial conversion price is RMB 40.73 per share. The adjustments to the conversion price are as follows:

Due to the Company’s completion on December 26, 2024 of the registration procedures for the vesting of the second vesting period under the 2022 restricted stock incentive plan for the first-granted portion and the vesting registration procedures for the first vesting period for the reserved portion, the Company’s total share capital increased from 210,928,884 shares to 210,959,781 shares. Because the total number of shares vested under the second vesting period for the first-granted portion and the first vesting period for the reserved portion under the 2022 restricted stock incentive plan represents a relatively small proportion of the Company’s total share capital, after completion of this vesting, the conversion price of “BrightGene Convertible Bond” remains unchanged at RMB 40.73 per share. For details, please refer to the Company’s announcement on January 8, 2025 on the website of the Shanghai Stock Exchange (www.sse.com.cn), entitled “Announcement of Shanghai BrightGene Bio-Medical Co., Ltd. on Not Adjusting the Conversion Price of the Convertible Corporate Bond ‘BrightGene Convertible Bond’” (Announcement No.: 2025-005).

Due to the Company’s implementation of its 2024 annual equity distribution, the conversion price of “BrightGene Convertible Bond” was adjusted from RMB 40.73 per share to RMB 40.58 per share effective May 14, 2025. For details, please refer to the Company’s announcement on May 7, 2025 on the website of the Shanghai Stock Exchange (www.sse.com.cn), entitled “Announcement of Shanghai BrightGene Bio-Medical Co., Ltd. on Adjusting the Conversion Price of the Convertible Corporate Bond ‘BrightGene Convertible Bond’” (Announcement No.: 2025-060).

Due to the Company’s completion on June 30, 2025 of the registration procedures for the vesting of the third vesting period under the 2022 restricted stock incentive plan for the first-granted portion and the vesting registration procedures for the second vesting period under the reserved portion, the Company’s total share capital increased from 210,961,003 shares to 211,609,573 shares. Because the total number of shares vested under the third vesting period for the first-granted portion and the second vesting period for the reserved portion under the 2022 restricted stock incentive plan represents a relatively small proportion of the Company’s total share capital, after completion of this vesting, the conversion price of “BrightGene Convertible Bond” remains unchanged at RMB 40.58 per share. For details, please refer to the Company’s announcement on July 3, 2025 on the website of the Shanghai Stock Exchange (www.sse.com.cn), entitled “Announcement of Shanghai BrightGene Bio-Medical Co., Ltd. on Not Adjusting the Conversion Price of the Convertible Corporate Bond ‘BrightGene Convertible Bond’” (Announcement No.: 2025-082).

Due to the Company’s completion on July 4, 2025 of the cancellation procedures for the compensation shares to be repaid pursuant to performance commitment, totaling 47,725 shares, the Company’s total share capital decreased by 47,725 shares. After cancellation of the repurchased shares, the conversion price of “BrightGene Convertible Bond” was adjusted from RMB 40.58 per share to RMB 40.59 per share. For details, please refer to the Company’s announcement on July 5, 2025 on the website of the Shanghai Stock Exchange (www.sse.com.cn), entitled “Announcement of Shanghai BrightGene Bio-Medical Co., Ltd. on Adjusting the Conversion Price of the Convertible Corporate Bond ‘BrightGene Convertible Bond’ and on Suspension and Resumption of Trading During Conversion” (Announcement No.: 2025-085).

Due to the Company’s completion on July 31, 2025 of the registration procedures for the vesting of the second vesting period for the second-category restricted stock under the 2023 restricted stock incentive plan, the Company’s total share capital increased from 211,571,033 shares to 212,098,693 shares. After completion of this vesting, the conversion price of “BrightGene Convertible Bond” was adjusted from RMB 40.59 per share to RMB 40.55 per share. For details, please refer to the Company’s announcement on August 2, 2025 on the website of the Shanghai Stock Exchange (www.sse.com.cn), entitled “Announcement of Shanghai BrightGene Bio-Medical Co., Ltd. on Adjusting the Conversion Price of the Convertible Corporate Bond ‘BrightGene Convertible Bond’ and on Suspension and Resumption of Trading During Conversion” (Announcement No.: 2025-098).

Due to the Company’s implementation of its 2025 interim equity distribution, the conversion price of “BrightGene Convertible Bond” was adjusted from RMB 40.55 per share to RMB 40.47 per share effective October 22, 2025. For details, please refer to the Company’s announcement on October 14, 2025 on the website of the Shanghai Stock Exchange (www.sse.com.cn), entitled “Announcement of Shanghai BrightGene Bio-Medical Co., Ltd. on Adjusting the Conversion Price of the Convertible Corporate Bonds Upon Implementation of the 2025 Interim Equity Distribution and on Resumption of Trading During Conversion” (Announcement No.: 2025-117).

Due to the Company’s completion on December 12, 2025 of the registration procedures for the second second vesting of the second vesting period under the 2023 restricted stock incentive plan for the second-category restricted stock, the Company’s total share capital increased from 212,100,363 shares to 212,103,653 shares. Because the total number of shares vested under the second second vesting of the second-category restricted stock for the second vesting period represents a relatively small proportion of the Company’s total share capital, after completion of this vesting, the conversion price of “BrightGene Convertible Bond” remains unchanged at RMB 40.47 per share. For details, please refer to the Company’s announcement on December 16, 2025 on the website of the Shanghai Stock Exchange (www.sse.com.cn), entitled “Announcement of Shanghai BrightGene Bio-Medical Co., Ltd. on Not Adjusting the Conversion Price of the Convertible Corporate Bond ‘BrightGene Convertible Bond’” (Announcement No.: 2025-129).

II. Conversion Status of the Convertible Bond This Time

The conversion period of “BrightGene Convertible Bond” runs from June 4, 2025 to November 27, 2030. From January 1, 2026 to March 31, 2026, a total of RMB 12,000 of “BrightGene Convertible Bond” was converted into the Company’s shares, with a conversion quantity of 295 shares, accounting for 0.0001% of the total number of shares issued by the Company prior to the conversion of “BrightGene Convertible Bond.”

As of March 31, 2026, a total of RMB 503,000 of “BrightGene Convertible Bond” has been converted into the Company’s shares, with a cumulative conversion quantity of 12,372 shares, accounting for 0.0059% of the total number of shares issued by the Company prior to the conversion of “BrightGene Convertible Bond.”

As of March 31, 2026, the amount of “BrightGene Convertible Bond” that has not yet been converted is RMB 821,847,000, accounting for 99.94% of the total issuance amount of “BrightGene Convertible Bond.”

III. Changes in Share Capital

Unit: shares

■

IV. Other

For investors who need to learn more about the detailed information of “BrightGene Convertible Bond,” please refer to the “Offering Prospectus for Convertible Corporate Bonds Issued to Non-Specific Investors” of Shanghai BrightGene Bio-Medical disclosed by the Company on November 26, 2024 on the website of the Shanghai Stock Exchange.

Contact Department: Securities Affairs Department

Telephone: 021-58338205

Email: hy@chemexpress.com

Contact Address: Building No. 3, No. 1999 Zhangheng Road, Pudong New Area, Shanghai

This announcement is hereby issued.

Board of Directors of Shanghai BrightGene Bio-Medical Co., Ltd.

April 2, 2026

Huge amounts of information and precise interpretation are available on the Sina Finance APP